



Toxicological Profile for Acrolein

Draft for Public Comment

May 2024



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute-, intermediate-, and chronic-duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S106-5
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA Section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health-related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under Section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
May 2024	Draft for public comment toxicological profile released
August 2007	Final toxicological profile released
December 1990	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P. (Lead)
Brittany Szafran, D.V.M., Ph.D.
Carolyn Harper, Ph.D.
Mohammad Shoeb, Ph.D.

Julie Melia, Ph.D., D.A.B.T.
Heather Carlson-Lynch, M.S., D.A.B.T.
Claire Heit, Ph.D.
Deborah M. Herber, Ph.D.
Jenny S. Crisman, B.S.
Ramsey Hanna, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. David Williams, Ph.D.; University Distinguished Professor; Department of Environmental and Molecular Toxicology; Oregon State University; Corvallis, Oregon
2. Robert Herrick, Sc.D.; Harvard School of Public Health; Department of Environmental Health; Boston, Massachusetts
3. Edward Levin, Ph.D.; Professor; Duke University; Durham, North Carolina

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs)	6
CHAPTER 2. HEALTH EFFECTS.....	10
2.1 INTRODUCTION.....	10
2.2 DEATH	67
2.3 BODY WEIGHT	68
2.4 RESPIRATORY	69
2.5 CARDIOVASCULAR.....	79
2.6 GASTROINTESTINAL.....	80
2.7 HEMATOLOGICAL	81
2.8 MUSCULOSKELETAL	83
2.9 HEPATIC.....	83
2.10 RENAL	85
2.11 DERMAL.....	86
2.12 OCULAR	86
2.13 ENDOCRINE.....	87
2.14 IMMUNOLOGICAL	88
2.15 NEUROLOGICAL.....	90
2.16 REPRODUCTIVE	91
2.17 DEVELOPMENTAL	92
2.18 OTHER NONCANCER.....	93
2.19 CANCER.....	93
2.20 GENOTOXICITY	95
2.21 MECHANISMS OF TOXICITY	98
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	102
3.1 TOXICOKINETICS.....	102
3.1.1 Absorption.....	103
3.1.2 Distribution	104
3.1.3 Metabolism.....	105
3.1.4 Excretion	108
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	109
3.1.6 Animal-to-Human Extrapolations	115
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	115

3.3 BIOMARKERS OF EXPOSURE AND EFFECT	117
3.3.1 Biomarkers of Exposure.....	118
3.3.2 Biomarkers of Effect.....	119
3.4 INTERACTIONS WITH OTHER CHEMICALS	119
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	121
4.1 CHEMICAL IDENTITY	121
4.2 PHYSICAL AND CHEMICAL PROPERTIES	121
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....	123
5.1 OVERVIEW	123
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	126
5.2.1 Production	126
5.2.2 Import/Export.....	128
5.2.3 Use	128
5.2.4 Disposal.....	128
5.3 RELEASES TO THE ENVIRONMENT.....	129
5.3.1 Air	129
5.3.2 Water.....	135
5.3.3 Soil	136
5.4 ENVIRONMENTAL FATE	137
5.4.1 Transport and Partitioning.....	137
5.4.2 Transformation and Degradation	138
5.5 LEVELS IN THE ENVIRONMENT.....	141
5.5.1 Air	142
5.5.2 Water.....	146
5.5.3 Sediment and Soil	147
5.5.4 Other Media	147
5.6 GENERAL POPULATION EXPOSURE.....	149
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	152
CHAPTER 6. ADEQUACY OF THE DATABASE	154
6.1 INFORMATION ON HEALTH EFFECTS.....	154
6.2 IDENTIFICATION OF DATA NEEDS.....	154
6.3 ONGOING STUDIES.....	162
CHAPTER 7. REGULATIONS AND GUIDELINES	163
CHAPTER 8. REFERENCES	165

APPENDICES

APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR ACROLEIN	B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR ACROLEIN	C-1
APPENDIX D. USER'S GUIDE.....	D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F. GLOSSARY	F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Inhalation Exposure to Acrolein.....	3
1-2. Health Effects Found in Animals Following Oral Exposure to Acrolein.....	4
1-3. Summary of Sensitive Targets of Acrolein – Inhalation	7
1-4. Summary of Sensitive Targets of Acrolein – Oral	8
2-1. Overview of the Number of Studies Examining Acrolein Health Effects.....	13
2-2. Levels of Significant Exposure to Acrolein – Inhalation	35
2-3. Levels of Significant Exposure to Acrolein – Oral.....	55
3-1. Metabolism of Acrolein.....	107
5-1. Number of NPL Sites with Acrolein Contamination.....	123
6-1. Summary of Existing Health Effects Studies on Acrolein by Route and Endpoint.....	155

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Acrolein	9
2-1. Levels of Significant Exposure to Acrolein – Inhalation	14
2-2. Levels of Significant Exposure to Acrolein – Oral.....	48
2-3. Levels of Significant Exposure to Acrolein – Dermal.....	64
2-4. Respiratory Lesions in Animals Following Inhalation Exposure to Acrolein.....	71
2-5. Respiratory Function in Animals Following Inhalation Exposure to Acrolein	75
2-6. Lung Weight in Animals Following Inhalation Exposure to Acrolein.....	76
2-7. RD ₅₀ Values in Animals Following Inhalation Exposure to Acrolein.....	77
2-8. Genotoxicity of Acrolein <i>In Vitro</i>	95
3-1. Metabolite Levels (Percent Sample Radioactivity) in Urine of Rats after Intravenous or Oral Dosing with 2.5 mg/kg Acrolein	108
4-1. Chemical Identity of Acrolein	121
4-2. Physical and Chemical Properties of Acrolein	122
5-1. Facilities that Produce, Process, or Use Acrolein.....	127
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Acrolein	130
5-3. Acrolein in Emissions from Combustion	132
5-4. Acrolein Emissions to the Air Based on 2017 National Emissions Inventory (NEI).....	133
5-5. Acrolein Emissions from Building Material.....	135
5-6. Lowest Limit of Detection Based on Standards	141
5-7. Summary of Environmental Levels of Acrolein.....	141
5-8. Acrolein Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	142
5-9. Summary of Annual Concentration of Acrolein (ppbv) Measured in Ambient Air at Locations Across the United States	143
5-10. Acrolein Concentrations (ppm) at Ground Level During Industrial Fires.....	144
5-11. Concentration of Acrolein ($\mu\text{g}/\text{m}^3$) Measured in Fresh and Aged Western U.S. Wildfire Smoke	144
5-12. Acrolein Concentrations in Indoor Air	145

5-13. Acrolein Content in Foods and Beverages	147
5-14. Reasonable Maximum Exposure of Acrolein for Daily Inhalation Dose and Administered Dermal Dose in $\mu\text{g}/\text{kg}/\text{day}$ for the Target Person.....	149
5-15. 3-HPMA Concentration ($\mu\text{g}/\text{g}$ creatinine) in Urine of Firefighters Pre- and Post-Fire Response.....	153
6-1. Ongoing Studies on Acrolein.....	162
7-1. Regulations and Guidelines Applicable to Acrolein.....	163